Lung Cancer in New Zealand: Patterns of Secondary Care and Implications for Survival

Stevens, Wendy; Stevens, Graham; Kolbe, John; Cox, Brian

doi:10.1097/jto.0b013e31805fea3a

Cited by 40 publications

(63 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study 28.57% patients (29.46% of NSCLC and 23.44% of SCLC) didn't receive any anticancer treatment. These figures varies from 19% in USA, 33% in Australia, 37% in Scotland, and 50% in Ireland and New Zealand (Fry et al, 1999;Vinod et al, 2008;Erridge et al, 2008;Mahmud et al, 2003;Stevens et al, 2007). Vinod et al (2010) have addressed this issue in their study and found that in actual practice 20% patients didn't receive any treatment; however guideline recommendations for no treatment were there in only 4% patients.…”

Section: Discussionmentioning

confidence: 99%

Clinico-pathological Profile of Lung Cancer at AIIMS: A Changing Paradigm in India

Malik¹,

Sharma²,

Mohanti³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Lung cancer is one of the commonest and most lethal cancers throughout the world. The epidemiological and pathological profile varies among different ethnicities and geographical regions. At present adenocarcinoma is the commonest histological subtype of non-small cell lung cancer (NSCLC) in most of the Western and Asian countries. However, in India squamous cell carcinoma has been reported as the commonest histological type in most of the series. The aim of the study was to analyze the current clinico-pathological profile and survival of lung cancer at our centre. Materials and Methods: We analyzed 434 pathologically confirmed lung cancer cases registered at our centre over a period of three years. They were evaluated for their clinical and pathological profiles, treatment received and outcome. The available histology slides were reviewed by an independent reviewer. Results: Median age was 55 years with a male:female ratio of 4.6:1. Some 68% of patients were smokers. There were 85.3% NSCLC and 14.7% SCLC cases. Among NSCLCs, adenocarcinoma was the commonest histological subtype after the pathology review. Among NSCLC, 56.8% cases were of stage IV while among SCLC 71.8% cases had extensive stage disease. Some 29% of patients did not receive any anticancer treatment. The median overall and progression free survivals of the patients who received treatment were 12.8 and 7.8 months for NSCLC and 9.1 and 6.8 months for SCLC. Conclusions: This analysis suggests that adenocarcinoma may now be the commonest histological subtype also in India, provided a careful pathological review is done. Most of the patients present at advanced stage and outcome remains poor.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinico-pathological Profile of Lung Cancer at AIIMS: A Changing Paradigm in India

Malik¹,

Sharma²,

Mohanti³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The discrepancy between studies might in part reflect a different population composition-that is, the Alberta population has a significantly smaller proportion of people of Asian ethnicity, a higher proportion of smokers, and a lower frequency of EGFR mutation compared with the other two provinces [37][38][39] . Internationally, the published rates of chemotherapy administration have all shown a favourable trend over time, although they vary widely, from less than 10% to more than 50% in developed countries 14,16,17,40 . Our outcomes would therefore be considered an outlier in comparison with those from other large retrospective studies.…”

Section: Figurementioning

confidence: 99%

“…Yet despite the demonstrated efficacy of systemic therapy, referral to mo after a diagnosis of advanced nsclc and administration of chemotherapy or targeted therapy remains suboptimal. The referral rates to mo are estimated to be 50%-70% for all nsclc patients and 30%-60% for all advanced nsclc patients [13][14][15][16][17] .…”

Section: Introductionmentioning

confidence: 99%

Reasons for Lack of Referral to Medical Oncology for Systemic Therapy in Stage Iv Non-small-cell Lung Cancer: Comparison of 2003–2006 with 2010–2011

Tudor

et al. 2017

Current Oncology

View full text Add to dashboard Cite

Introduction Only approximately 25% of stage iv non-small-cell lung cancer (nsclc) patients receive systemic therapy. For such patients, we examined factors affecting referral to a cancer centre (cc) and to medical oncology (mo), and use of systemic therapy. were referred to a cc, with 22% and 23% receiving traditional chemotherapy (tctx). Referral to a cc or mo and use of tctx correlated with survival (p < 0.0001): The mos duration was 11.2 months in those receiving tctx and 1.0 months in those not referred to a cc. The overall mos duration was similar in the two cohorts (4.1 months vs. 3.9 months, p = 0.47). Major reasons for lack of referral to mo included poor functional status, rapid decline, and patient wish, which were similar to the reasons for forgoing tctx. In the two cohorts, 87 (9.4%) and 42 (7.5%) patients received epidermal growth factor inhibitors, with a mos duration of 16.2 months. Multivariable analysis showed that male sex [hazard ratio (hr): 1.16; p = 0.008] and pulmonary embolus (hr: 1.2; p = 0.002) correlated with worse survival. In contrast, receipt of chemotherapy (hr: 0.5; p < 0.001) and enrolment in a clinical trial (hr: 0.76; p = 0.049) correlated with better survival. Methods ConclusionsOur experience confirms that, over time, uptake of systemic therapy, including tctx and targeted therapy, changed little despite their established efficacy. Most of the factors limiting systemic therapy uptake appear to be non-modifiable at the time of referral. Rapid diagnosis and the availability of well-tolerated drugs for all nsclc patients will likely be the most important factors in increasing systemic therapy uptake in this population.

show abstract

“…[15][16][17][18][19][20] have addressed this issue in their study and found that in actual practice 20% patients didn't receive any treatment; however, guideline recommendations for no treatment were there in only 4% patients.…”

Section: Discussionmentioning

confidence: 99%

Clinico-pathological profile of lung cancer in North Indian population

Bhaskar

Singh

et al. 2018

IJRDPL

View full text Add to dashboard Cite

Lung cancer is the most common cancer representing approximately 12% of all new cancers. It is also the most frequent type of cancer in males and remains the most a common cause of cancer-related mortality in both sexes. An increasing incidence of lung cancer has been observed in India. We studied the clinical and pathological profile of patients with lung cancer in a tertiary care center. We performed a retrospective analysis of histopathologically proven cases of bronchogenic carcinoma admitted in our hospital. In our study we included 203 patients with confirmed cases of lung cancer. Male to female ratio was 8.2:1. The common age group being 40-60 years, 9.86% of the patients were less than 40 years old age. Smoking was found to be the main risk factor for 81.77% patients. The most frequent symptom was a cough (72.90%) followed by fever (58.12%). The most common radiological presentation was mess lesion (46.31%). The most common histopathological type was squamous cell carcinoma (SCC) (44.83%) followed by adenocarcinoma (19.78%) and small cell lung carcinoma (SCLC) (16.75%). The majority patients (73.29%) were diagnosed in the later stages of the disease (3b and 4). Squamous cell carcinoma was the most frequent histopathological form. Smoking remains the major risk factor for lung cancer.

show abstract

Lung Cancer in New Zealand: Patterns of Secondary Care and Implications for Survival

Cited by 40 publications

References 36 publications

Clinico-pathological Profile of Lung Cancer at AIIMS: A Changing Paradigm in India

Clinico-pathological Profile of Lung Cancer at AIIMS: A Changing Paradigm in India

Reasons for Lack of Referral to Medical Oncology for Systemic Therapy in Stage Iv Non-small-cell Lung Cancer: Comparison of 2003–2006 with 2010–2011

Clinico-pathological profile of lung cancer in North Indian population

Contact Info

Product

Resources

About